Traws Pharma Announces Up to $60 Million Private Placement Financing
MWN-AI** Summary
Traws Pharma, Inc., a clinical-stage biopharmaceutical company specializing in respiratory viral disease therapies, has announced a significant private placement financing of up to $60 million, aimed at advancing its influenza program. The financing, led by Sirenia Capital Management LP, includes an initial $10 million in gross proceeds from new and existing institutional investors, with up to $50 million available through milestone-based warrants over the next three years.
The financing structure comprises several components: a $10 million upfront funding at a price of $1.6730 per share, alongside three types of warrants. The Series A warrant could generate an additional $10 million upon approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for a human challenge trial involving Traws' investigational drug, tivoxavir marboxil. Furthermore, the Series B and Series C warrants can each yield up to $10 million and $30 million, respectively, upon achieving specific milestones related to the challenge trial results and shareholder approval.
Iain Dukes, the CEO of Traws Pharma, expressed optimism about the financing, stating it positions the company to move forward with the challenge trial while maintaining access to further capital as development milestones are reached. The financing was finalized on April 15, 2026, with funding expected to be received the following day, contingent upon customary closing conditions.
Notably, the securities offered will not be publicly registered, adhering to regulatory exemptions, and Traws has committed to filing for a registration statement to facilitate the resale of common stock and warrants. Traws Pharma's broader mission focuses on developing innovative antiviral therapies, particularly targeting influenza and other respiratory threats.
MWN-AI** Analysis
Traws Pharma's recent announcement regarding a PIPE financing, amounting to up to $60 million, is a significant development for the company as it moves forward with its influenza program. Led by Sirenia Capital Management LP, this financing positions Traws to advance its pivotal human challenge trial for tivoxavir marboxil, a drug designed to combat respiratory viral diseases. The initial $10 million infusion is crucial for immediate liquidity, allowing the company to complete regulatory milestones and maintain operations while minimizing dilution for existing shareholders.
Investors should pay close attention to the terms of the financing. Traws Pharma has set up milestone-based warrants with potential proceeds that could significantly enhance its capital reserves upon successful completion of the Challenge trial and other milestones. These warrants provide a mechanism for existing and new investors to benefit from the company’s future success and highlight confidence in its clinical trajectory.
Given Traws Pharma's focus on respiratory viruses, this financing comes at a time when global health concerns regarding influenza and other respiratory infections continue to grow. With the potential for tivoxavir marboxil to be a game-changer in prophylactic treatment and management, market interest in the company could increase, reflecting a breeding ground for bullish sentiment.
However, potential investors should remain cautious. Traws is still navigating the complexities of clinical trials and regulatory approvals, a process that carries inherent risks. The mention of a current FDA clinical hold on their IND filing highlights this uncertainty. Therefore, while the financing provides a solid foundation for growth, investors should maintain a balanced view, considering both the promising potential and the risks involved. In summary, Traws Pharma's financing offers an intriguing investment opportunity, but due diligence is essential in this high-stakes biotech sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Financing led by Sirenia Capital Management LP advances Traws Pharma's influenza program through a human challenge trial for tivoxavir marboxil in the United Kingdom
NEWTOWN, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, “Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced that it has entered into a securities purchase agreement with new and existing institutional and accredited investors for a private investment in public equity (“PIPE”) financing expected to provide approximately $10.0 million in gross proceeds at closing. The financing will position Traws Pharma to complete the Challenge trial, in the United Kingdom (“Challenge Trial”) and includes up to $50 million of additional gross proceeds from milestone-based and three-year warrants.
The April 2026 financing consists of (i) $10.0 million of upfront gross proceeds at a purchase price of $1.6730 per share from the sale of common stock (or pre-funded warrants in lieu thereof), (ii) a milestone-based Series A warrant with potential additional aggregate gross proceeds of approximately $10.0 million if fully exercised upon receipt of approval from the Medicines and Healthcare products Regulatory Agency (“MHRA”) to conduct a human challenge trial in the UK, (iii) a milestone-based Series B warrant with potential additional aggregate gross proceeds of approximately $10.0 million if fully exercised following both shareholder approval and the announcement of data from the challenge trial, and (iv) a Series C warrant with a three-year term providing potential additional aggregate gross proceeds of approximately $30.0 million if fully exercised following shareholder approval. The PIPE was priced “at-the-market” under the rules and regulations of The Nasdaq Stock Market LLC, with each warrant having an exercise price equal to the deal price.
“We are pleased to announce this financing and the support of existing and new investors,” said Iain Dukes, MA, DPhil, Chief Executive Officer of Traws Pharma. “The capital from this financing positions us to advance our influenza program through a human challenge trial in the UK while preserving access to additional capital as we achieve key development milestones.”
The financing was completed on April 15, 2026, with funding thereunder expected April 16, 2026, subject to the satisfaction of customary closing conditions. The terms of the financing are described in more detail in the Company’s current report on Form 8-K to be filed in connection with the financing.
Cantor Fitzgerald & Co. acted as lead placement agent for the PIPE financing.
Citizens JMP Securities, LLC and Tungsten Advisors LLC (through its Broker-Dealer, Finalis Securities LLC) acted as co-placement agents.
The offer and sale of the foregoing securities are being made in a transaction not involving a public offering, and the securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws. Pursuant to a registration rights agreement, the Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) registering the resale of the shares of common stock and shares underlying the warrants and pre-funded warrants, if any, issued in the financing.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer, solicitation or sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. Any offering of the securities under the resale registration statement will only be made by means of a prospectus.
About Traws Pharma, Inc.
Traws Pharma is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. Traws integrates antiviral drug development, medical intelligence and regulatory strategy to meet real world challenges in the treatment of viral diseases. We are advancing novel investigational oral small molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: seasonal influenza and H5N1 bird flu, and COVID-19/Long COVID. Tivoxavir marboxil is in development as a once-monthly oral prophylactic agent for influenza prevention, with additional potential as a single-dose therapy for seasonal flu or H5N1 bird flu, targeting the influenza cap-dependent endonuclease (CEN). Ratutrelvir is in development as a ritonavir-independent COVID treatment, targeting the Main protease (Mpro or 3CL protease).
Traws is actively seeking development and commercialization partners for its legacy clinical oncology programs, rigosertib and narazaciclib. More details can be found on Traws’ website at https://www.ir.trawspharma.com/partnering.
For more information, please visit www.trawspharma.com and follow us on LinkedIn.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties including statements regarding the Company, its business and product candidates, including the expected timing and satisfaction of conditions for the closing of the PIPE financing, the expected upfront and potential additional proceeds from the financing, the terms and potential exercise of the Series A, Series B and Series C common warrants, the Company’s anticipated regulatory and clinical milestones, the advancement of the Company’s influenza program and planned challenge study in the United Kingdom, and the expected use of proceeds from the financing. The Company has attempted to identify forward-looking statements by terminology including “believes”, “estimates”, “anticipates”, “expects”, “plans”, “intends”, “may”, “could”, “might”, “will”, “should”, “preliminary”, “encouraging”, “approximately” or other words that convey uncertainty of future events or outcomes. Although Traws believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, these statements are subject to risks and uncertainties that could cause actual results to differ materially, including risks related to satisfaction of closing conditions, market and other conditions, the Company’s ability to achieve the applicable warrant-triggering milestones, the Company’s ability to advance the challenge study and other development activities on the expected timeline, the Company’s need for additional capital, and the other risks described from time to time in the Company’s filings with the Securities and Exchange Commission. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the outcome of Traws’ IND filing with the FDA for tivoxavir marboxil, including the current FDA clinical hold; the success and timing of Traws’ clinical trials; and those discussed under the heading “Risk Factors” in Traws’ filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. Traws undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except to the extent required by law.
Traws Pharma Contact:
Charles Parker
Traws Pharma, Inc.
cparker@trawspharma.com
www.trawspharma.com
Investor Contact:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com
FAQ**
How does the recent PIPE financing for Traws Pharma Inc. TRAW directly impact the timeline and anticipated outcomes of the influenza challenge trial in the UK?
What are the specific milestones tied to the Series A, B, and C warrants in the PIPE financing for Traws Pharma Inc. TRAW, and how might they influence investor confidence?
Given the clinical-stage nature of Traws Pharma Inc. TRAW, what risks does the company face in meeting the milestones necessary to fully exercise the additional warrant proceeds?
Can you elaborate on the strategic importance of the Challenge trial for Traws Pharma Inc. TRAW in the context of emerging respiratory viral threats and the potential competitive landscape?
**MWN-AI FAQ is based on asking OpenAI questions about Traws Pharma Inc. (NASDAQ: TRAW).
NASDAQ: TRAW
TRAW Trading
8.13% G/L:
$1.6869 Last:
571,383 Volume:
$1.55 Open:
